Clinical Pharmacology and Prescribing

Adele Print2021Pharmacist – Auckland DHBProfessional Teaching Fellow - School of Pharmacy



Relevant Clinical Pharmacology Module Learning Outcomes

Domain: Clinical and Communication Skills

- Demonstrate foundation skills for safe and effective prescribing
- Explain the information patients and medical practitioners need before prescribing a medicine
- Write a prescription correctly

Objectives

- Recognise the importance of clinical pharmacology as the scientific discipline that underpins a rational approach to prescribing medicines
- Summarize the knowledge and skills required to:
 - Prescribe drugs safely, effectively and economically
 - Write legal prescriptions that take into account the needs of individual patients
- Describe the factors that influence the choice of medicine and dose
- Explain the importance of monitoring the impact of drug therapy and describe the ways in which therapy can be monitored

Why learn about "Clinical Pharmacology" and "Therapeutics"?

- Pharmacological knowledge is essential to appropriate prescribing, and has been identified by junior doctors as an area to be strengthened in their training.
- Safe prescribing is not just about writing a prescription, but involves many cognitive and decision-making steps.

Elaine Lum et al. The competent prescriber: 12 core competencies for safe prescribing. Australian Prescriber. Volume 36 Number 1, pages 13-16, February 2013.



- As newly qualified doctors you will be called upon to prescribe drugs many times every day.
- You need to be able to do it safely and effectively.

Rational Prescribing

Rational prescribers should attempt to:

- maximise clinical effectiveness
- minimize harms
- avoid wasting scarce healthcare resources
- respect patient choice.

Maxwell S. Rational prescribing: the principles of drug selection. Clin Med 2016.







In order to choose a medicine you need to consider...

Efficacy

Safety

Appropriateness

Adherence

Efficacy of a medicine

How effective are the treatment alternatives?

- What is the evidence to support these treatment alternatives?

Sources of information include

- Colleagues
- Conferences
- Review articles
- Guidelines

• There may be patient and medicine factors to consider

- Age, gender
- Interacting diseases
- Interacting medicines or foods
- Patient choice and adherence
- Pregnancy, lactation
- Pharmacogenetics



http://sgugenetics.pbworks.com/w/page/47491904/What%20Is%20Pharmacogenomics

Safety of a medicine

- What are contraindications for using this drug in general and specifically in this patient?
 - Allergies
 - Concomitant disease including major organ failure
- What are common and potentially serious adverse effects that can occur with this drug?
 - Will these side effects affect my choice for this patient?
- What drug interactions need to be considered?
 - Drug-drug, drug-food, drug-disease interactions
- Is the patient pregnant or lactating?

Appropriateness of a medicine

- Can the patient afford it?
- Are there any considerations that need to be made for adherence?
 - Patient's perspective, health beliefs
 - Dosing factors timing, empty stomach etc
 - Needs blood tests and dose adjustments
- Consider non-pharmacological options

Jatrana, S., Crampton, P., & Norris, P. (2011). Ethnic differences in access to prescription medication because of cost in New Zealand. *Journal of Epidemiology & Community Health*, *65*(5), 454-460.



Choose a "route of delivery"

IV injectio

High concentrations in the blood rapidly Instant and complete absorption Potentially more dangerous

Skin patches and gels

Lower peak concentration and extended duration of effect

Can bypass first pass metabolism Skin reaction is potential adverse effect

Depot preparations

Release contents slowly over hours months May improve adherence Require a deep injection

Local delivery Site of action can be targeted Reduces systemic effects

Oral tablets

Slower rise to a later peak concentration May be less complete absorption May be subject to first pass metabolism



There is certain information that is essential for a legal prescription

- Prescriber details
- Full name
- Prescriber's signature
- Workplace Address
- MCNZ registration
 number
- Contact phone number

- Patient details
- Full name
- Residential address
- Date of Birth (if under the age of 13 years)

It is essential that the prescription is legible

Pr	esci	ipti	on Form	Sally S	Smith	1971	_	Item Count
Circl Y 1 Z	le one fr J (Circl High	om eac A 3 e if patie Use Hea	h line O nt has lith Card)	11223 NZMC 021 44 Ward / Dep	C Reg. No.: 15566	: Extn.	ha	Does patient we Prescription Subsidy Card?
Nam MR M N Full F	e of Patie MASTER ficha Residentia	MRS MI	SS MS (Circle one) Wrence ss of Patient					
G	UA Gi Frafto	raftoi n, Au	n Road Ickland					
Date	of Birth -	If patier /	nt under 13.		Period Quantity [[Disp.	Dispensing Date	Pharmacist Initials

	Quantity	Disp.	of Repeat	Initials			
R.		1st					
*X		2nd					
		3rd					
p.		1st					
*X		2nd					
		3rd					
	1 dat						
R _X		and					
		2nd					
		Sid					
		1.01					
^R X		2nd					
		3rd					
		Siu					
	Substitution not permitted on this	prescr	iption unless sp	ecified in writi			
Centiled Extended Supply:	S. Smith	09/07/2		/07/2021			
1664681	Signature of Prescriber			Date			
	orginations of Presender		and the second				

Each prescription has three parts

	Quantity	Disp.	of Repeat	Initials	
R Englanril 10mg tab	lat	1st			
-X Enalapin Tong tab	let	2nd			
Sig: i BD po		3rd			
M: 30 days supply					
· · · · ·		Int			
PX		Ist			
		2nd			
		ara			
R.		1st			
*X		2nd			
		3rd			
D		1st			
ľX		2nd			
		3rd			
			-		
	Substitution not permitted on this	t permitted on this prescription unless specified in writin			
Jantised Extended Supply;					
1004001				1 1	
1004081	Signature of Prescriber			Date	



• These can be more detailed.

 For warfarin this may be written as:
 Sig: 2mg nocte po
 Take the dose as prescribed, according to the INR blood tests.

Third Part – M or Mitte (translates as 'send to a total of')

- These are the instructions for the pharmacist.
- Total amount of medicine or Total period of supply
- For enalapril this may specify thirty days supply: M: 30 days supply

• The maximum period of supply is 3 months except for oral contraceptive which is 6 months supply.

Commonly used abbreviations

Administration	
ac	before food
сс	with food
рс	after food

Frequency	
BD	twice daily
mane	morning
midi	midday
nocte	night
prn	when required (as needed)
q4h	every four hours
qóh	every six hours
q8h	every eight hours
q12h	every twelve hours
QID	four times a day
STAT	immediately
TDS	three times a day

https://www.hqsc.govt.nz/assets/Medication-Safety/NMC-PR/NMC-UserGuide-Oct2012.pdf

Commonly used abbreviations

Route	
buc	buccal
IM	intramuscular
inh	inhalation
IV	intravenous
neb	nebuliser
ng	nasogastric
ро	oral
pr	per rectum
pv	per vagina
nj	nasojejunal
subcut	subcutaneous
subling	sublingual
top	topical
PEG	percutaneous endoscopic gastrostomy

Abbreviations to **avoid for safety reasons**

µg or mcg	microgram	Mistaken as mg (milligrams).	Write microgram.
U or IU	U = unit	Mistaken U as zero, four, and cc.	Write unit or international unit.
	IU = international unit	Mistaken IU as IV (intravenous), 10 (ten), or as a trailing 1 (one).	-
ng	nanogram	Mistaken as milligram.	Write nanogram.
OD, od, or O.D.	once a day, daily or every day	Mistaken as QID (four times a day) or BD (twice daily).	Write daily or the intended time of administration (eg, morning, night).
Q.D, q.d, qd, QD	every day (in USA only)	Mistaken as QID or BD.	Write daily or the intended time of administration (eg, morning, night).
SC	subcutaneous	Mistaken as SL (sublingual).	Write subcut or subcutaneous.
SL or S/L	sublingual	Mistaken as SC (subcutaneous).	Write subling or sublingual.

See additional abbreviations to avoid in the link below:

https://www.hqsc.govt.nz/assets/Medication-Safety/Watch-Updates/Medication-Safety-Watch-2-May12.pdf



Patient Education

- Medicine name and dose
- How and when to take it
- Reason(s) for prescribing medicine
- Benefits of treatment and when they should occur
- Possible adverse effects and how to manage them
- Possible interactions with food, drink and medicines
- Timing of follow-up

Don't provide too much information when patient is not able to assimilate it (e.g. when worrying about other issues)

Makoul G, et al. Social Science & Medicine, 41 (1995), pp. 1241-1254.

PRESCRIPTION

ave

What else can you do?

- Provide sources of further information
- Discuss aids to adherence e.g. medicine cards, adherence packs

 Image: Sector Sector

http://www.douglas.co.nz/compliance-packaging/products/medico-pak/

Health and Disability Code of Rights

- Right 5
- The right to effective communication
- Right 6
- The right to be fully informed
- Right 7
- The right to make an informed choice and give informed consent



https://www.hdc.org.nz/your-rights/the-code-and-your-rights/









Review medicines at regular intervals

- Offer repeat information and review to patients, especially when treating long-term conditions with multiple medicines
- Any plan should include the goal(s) of therapy and a date for a follow up review

Adapted from http://www.nice.org.uk/guidance/cg76/resources/cg76-medicines-adherence-full-guideline2.



Example Short answer question

Describe FOUR aspects related to the safety of a medicine you would consider before prescribing